From Cancer Genomics to Precision Oncology-Tissue's Still an Issue
From Cancer Genomics to Precision Oncology-Tissue's Still an Issue
复制标题
DOI：
10.1016/j.cell.2014.05.027
复制
发表时间：
2014-06-19
期刊：
影响因子：
64.5
通讯作者：
Settleman, Jeff
中科院分区：
文献类型：
--
作者：
Cohen, Robert L.;Settleman, Jeff
快速发展的基因组技术使得对有限的肿瘤活检材料进行广泛的分子分析成为可能，从而促进了个性化癌症医学的更广泛实施。然而，基于基因组学的不同肿瘤类型的患者分层不太可能取代在解决临床需求方面的组织起源考虑，包括开发和应用新的“合理靶向”癌症治疗。
Rapidly evolving genome technology has enabled extensive molecular analysis of limited tumor biopsy material, thereby facilitating the broader implementation of personalized cancer medicine. However, genomics-based patient stratification across diverse tumor types is unlikely to supplant tissue-of-origin considerations in addressing clinical needs, including the development and application of novel "rationally targeted" cancer therapies.